

Docket No. 2016-4010US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) :

Jason D. Bannan et al.

Serial No.

09/335,581

Group Art Unit: 1645

Filed

June 18, 1999

Examiner: Ja-Na Hines

For

PEPTIDES USEFUL FOR REDUCING SYMPTOMS OF TOXIC

SHOCK SYNDROME AND SEPTIC SHOCK

STATEMENT UNDER 37 C.F.R. §1.821(f) OR §1.825(b)

Commissioner for Patents Washington, D.C. 20231

ATTENTION: Lynette R.F. Smith

Supervisory Patent Examiner Technology Center 1600

RECEIVED

DEC 0 7 2001

TECH CENTER 1600/2900

Dear Sir:

I hereby certify that:

[] The paper Sequence Listing and computer readable form containing the Sequence Listing submitted herewith are identical. (37 C.F.R. §1.821(f)).

[X] The substitute paper Sequence Listing and substitute computer readable Sequence Listing submitted herewith are identical. No new matter is included (37 C.F.R. §1.825(b)).

Respectfully submitted, Morgan & Finnegan, L.L.P.

Dated: November 15, 2001

By:

Mary J. Morry

Reg. No. 34,398

Mailing Address:

MORGAN & FINNEGAN, L.L.P. 345 Park Ave. New York, NY 10154 (212) 758-4800 Telephone (212) 751-6849 Facsimile

664264 v1

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
x	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
Ļ	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
x	7. Other: The newly submitted sequences have not been submitted in computer readable form. RECEIVED
	DEC 0 7 2001
Applicant Must Provide:	
X	An initial or <u>substitute</u> computer readable form (CRF) copy of the "Sequence Lis too H CENTER 1600/290
X	An initial or <u>substitute</u> paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
×	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
Fo	r questions regarding compliance to these requirements, please contact:
Fo	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support Technical Assistance703-287-0200
	To Purchase Patentin Software703-306-2600
	PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY